GR2301 injection

BIOLOGICAL3 trials

Sponsors

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Conditions

Healthy Adult ParticipantsHealthy SubjectsMultiple DoseSingle Ascending DoseVitiligo

Phase 1

A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.

Not yet recruitingNCT07190716

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Healthy Subjects, Single Ascending Dose

Start: 2025-10-10End: 2026-05-30Target: 36Updated: 2025-09-24

A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo

Not yet recruitingNCT07647237

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Vitiligo

Start: 2026-06-01End: 2028-12-01Target: 116Updated: 2026-06-15

A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

Not yet recruitingNCT07647224

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Healthy Adult Participants, Multiple Dose

Start: 2026-06-01End: 2027-07-01Target: 36Updated: 2026-06-15